Finnhub•2026-04-21
Polaryx Therapeutics Gets FDA Fast Track Designations for Its Lead Drug CandidatePLYX — Polaryx Therapeutics, Inc
NASDAQ · Pharmaceuticals · Pharmaceuticals
$5.70-83.71%Market cap297.32M
- Latest Close
- $5.7
- 30-Day Move
- -83.7%
- Market Cap
- $297M
- Latest Revenue
- $0
NASDAQ:PLYXPharmaceuticals / PharmaceuticalsDelayed public snapshot
Polaryx Therapeutics, Inc
A read-only Alphactor snapshot forPolaryx Therapeutics, Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-20
Topline snapshot
Latest Close
$5.7
30-Day Move
-83.7%
Market Cap
$297M
Latest Revenue
$0
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$5.70
-83.7%last 90 delayed daily bars
Market cap$297M
90D High
$48.91
90D Low
$2.20
Avg Volume
2,064,191
What stands out
PLYX is down 83.7% over the last 30 trading days shown on this page.
Latest operating income is $-911,000, which helps anchor the headline ratios with an actual earnings figure.
Research snapshot
Dark Pool Short %
41.8%
Fundamentals snapshot
Latest Close
$5.7
30-Day Move
-83.7%
Market Cap
$297M
Latest Revenue
$0
Financial statement snapshot
Revenue
$0
Gross Profit
--
Operating Income
$-911,000
Net Income
$-1M
Gross Margin
--
Net Margin
--
Current Ratio
--
Debt / Equity
--
Quality snapshot
Altman Z
263.95
Safe
Piotroski
2
Weak (0-3)
Cash Conversion
0.44x
Rule of 40
--
Insufficient data
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2023-12-31 | $0 | $-4M | $-4M | $-173,000 |
| 2024-12-31 | $0 | $-4M | $-30M | $-3M |
| 2025-12-31 | $0 | $-8M | $-9M | $-4M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
Finnhub•2026-04-21
Polaryx Therapeutics receives U.S. FDA fast track designations for all four indications to be evaluated in the Soteria Basket TrialBenzinga•2026-04-21
Polaryx Therapeutics Says FDA Grants Fast Track Designation To PLX-200 For Treatment Of JNCL/CLN3 Disease, Krabbe Disease, And Sandhoff DiseaseFinnhub•2026-04-15
Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric CareAfter signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
Insider activity snapshot
Buy Value
$7,990.62
Sell Value
$0
Buys
1
Sells
0
Buy Value
$7,990.62
Sell Value
$0
Buy/Sell Ratio
1.00x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
Recent insider transactions
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-02-18 | Landis G. Michael | Buy | 2,867 | $2.79 |
Dark-pool activity snapshot
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.